of the population is thought to be diabetic (that is, over one million diabetics in England and Wales). The prevalence of blindness due to retinopathy in diabetics has been calculated3 as 1.900; thus the total of diabetics blind from retinopathy is close to 20 000, a figure over double that estimated by the Committee on Blindness of a Working Party of the British Diabetic Association .
Visual loss may, however, be prevented by photocoagulation, and more widespread (and judicious) application of this treatment may well reduce the numbers of diabetics who go blind. All concerned with the care of diabetics need to be aware of the natural history of diabetic retinopathy and the indications for referral for treatment.
Diabetic retinopathy may be divided into background retinopathy and proliferative retinopathy. Some 26) . They used the argon laser for treatment, and when visual acuity changed by two lines on the Snellen chart the eye was considered "better" or "worse." At evaluation the untreated eyes had deteriorated compared with the treated (P <0 001), though the difference was only significant when the initial visual acuity was 6/36 or better. A British multicentre trial using xenon arc photocoagulation for maculopathy largely confirmed these findings.7 In this trial 76 patients were seen after one, 44 after two, and 25 after three years. The treated eyes retained significantly better visual acuity than the untreated at each yearly assessment, and in patients with an initial visual acuity of 6124 or better more untreated eyes deteriorated by more than two lines of Snellen. As Patz's study found, there was no significant difference between treated and untreated eyes with initial visual acuity of 6/36 or less, suggesting that eyes so severely affected have reached a stage unresponsive to treatment. In this trial over a quarter of all eyes which became blind did so from proliferative retinopathy which had developed since entry into the trial, showing that maculopathy and proliferative retinopathy are not mutually exclusive. The The results of these randomised controlled trials suggest that photocoagulation is of considerable benefit when new vessels arise from the disc and in eyes with proliferative changes and a previous history of vitreous haemorrhage. Both these features carry a poor prognosis. The report from Hercules et al°s uggests that treatment may also be effective even when proliferative changes are accompanied by moderate amounts of fibrous tissue-usually a feature of advanced disease. The optic disc can be seen fairly easily during examination with an ophthalmoscope, and detecting new vessels there should be part of the regular routine follow-up of all diabetic patients. Physicians need to be aware of the symptoms of vitreous haemorrhage, and they should look for signs of proliferative retinopathy when patients complain of floaters, especially if accompanied by a drop in visual acuity. While peripheral retinal new vessels pose a less immediate threat, these can still produce visual loss by spread to the macula, and disc vessels are apt to appear as a later feature. Patients with all forms of proliferative retinopathy should be regularly and carefully reviewed in order to assess their suitability for treatment to prevent development of irreversible changes or complete blindness.
The macula is not easily seen without dilatation of the pupil. When, however, there is a drop in visual acuity, either subjective or objective in patients in the older age group, maculopathy should be suspected-especially in the presence of moderate or severe background retinopathy. More use should be made of ophthalmic opticians to provide a refracting service so that the eyes can be tested for corrected visual acuity, but the judicious use of pin-hole testing is 
